Stockreport

Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com
PDF ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS SECOND YEAR OF PHASE 3 CARDINAL TRIAL CONTINUING [Read more]